Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...

In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma. Researchers sought to determine whether ...

A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus Erythematosus (SLE). Preliminary data suggests that CAR-T therapy may ...

As cancer-killing CAR-T cells course through the body, they make occasional pit stops at the gut. What they do there — and which gut microbes they meet up with — could potentially change the prospects ...

There's probably not a hotter area of biotechnology right now than what's known as CART therapy, in which a patient's own white blood cells are genetically engineered to attack cancer. Earlier this ...

Please provide your email address to receive an email when new articles are posted on . “It was a huge surprise, I have to say,” Georg Schett, MD, of Friedrich Alexander University Erlangen-Nuremberg ...

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival Eleven ...

Yesterday Celgene finalized its acquisition of Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B. With only a few hundred patients ever treated with their ...